Teflaro (Ceftaroline Fosamil Acetate) Patent Expiration, LOE Window & CMS Spending

Teflaro (Ceftaroline Fosamil Acetate) by AbbVie: FDA Orange Book LOE 2031-02-10, 0 AB generics, $19.0M 2024 CMS Part D & Medicaid spend, and $2,336 CA SB 17 specialty launch WAC.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorAbbVie
FDA Application & PathwayN200327 (NDA)
Exclusivity / Cliff HorizonMid-Term Protection (2031-2035)
Core Active-Ingredient LOE DateNot listed / N/A
Last Listed Patent or Exclusivity Date2031-02-10
Orange Book Patents (*PED Extensions)2 patents (0 *PED)
Active AB-Rated Generic Competitors0
2024 CMS Total Public Spend$19.0M
2024 Medicare Part D Spend$12.5M
2024 Medicaid Spend$6.4M
Reported Wholesale Price Change (CA SB 17)Specialty launch notice ($2,336 intro WAC)

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for AbbVie across sibling Meru public-data platforms.